
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx Inc has demonstrated robust financial growth, achieving a 25% increase in top-line revenue during Q4, supported by a 17% rise in volume and a 5% lift in average selling prices, along with record revenue from patient and digital solutions. The company has shown consistent performance with a 21% revenue growth in Q3, driven by a 13% increase in volume, setting a historic high in cash collections in October. Additionally, CareDx is projected to see continued growth, raising revenue estimates for 2026 and 2027 due to anticipated high returns on investment from a significantly expanded sales force, positioning the company for further sales volume increases moving forward.
Bears say
CareDx Inc is facing a challenging financial outlook, highlighted by a projected $7.5 million negative revenue impact tied to upcoming LCD decisions, which reflects a significant portion of its annualized revenue. Additionally, revenue performance has shown signs of weakness, with Q3'25 testing volumes falling short of expectations despite a year-over-year increase, indicating potential issues with sustaining growth. Moreover, the company is trading at low multiples relative to both its revenue estimates and historical market averages, suggesting investor concerns regarding its ability to successfully commercialize new diagnostic solutions critical to its growth strategy.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares